etanidazole has been researched along with atrasentan in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Cho, H; Koutcher, JA; Li, XF; Ling, CC; Lupu, ME; Russell, J; Yang, KM | 1 |
1 other study(ies) available for etanidazole and atrasentan
Article | Year |
---|---|
Atrasentan (ABT-627) enhances perfusion and reduces hypoxia in a human tumor xenograft model.
Topics: Adenocarcinoma; Animals; Atrasentan; Colonic Neoplasms; Combined Modality Therapy; Etanidazole; Gadolinium DTPA; HT29 Cells; Humans; Hydrocarbons, Fluorinated; Hypoxia; Magnetic Resonance Imaging; Male; Mice; Mice, Nude; Nitroimidazoles; Perfusion; Pyrrolidines; Radiation-Sensitizing Agents; Radiotherapy; Treatment Outcome; Xenograft Model Antitumor Assays | 2009 |